ImmuneOnco Biopharma Trials

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

timdarpacept (IMM01) / ImmuneOnco Biopharma

NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting

202

Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Classic Hodgkin Lymphoma

06/26

07/29

CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia

Recruiting

170

RoW

IMM01, Timdarpacept, Azacitidine, Placebo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Chronic Myelomonocytic Leukemia

04/26

10/29

DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting

RoW

IMC-001, Not confirm yet

ImmuneOncia Therapeutics Inc.

Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma

07/24

02/26

TMB-H, NCT06365840: A Study of IMC-001 In Patients With Metastatic Or Locally Advanced Solid Tumor

Recruiting

RoW

IMC-001

ImmuneOncia Therapeutics Inc.

TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

12/26

08/29

NCT06788431: A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS

Recruiting

RoW

IMC-001, Optimal medical treatment

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., The First Affiliated Hospital of Nanyang Medical College, Renji Hospital, Shanghai

Atherosclerosis

11/25

12/25

IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1b/2

309

RoW

IMM01, SIRPα Fc, Tislelizumab

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Solid Tumor, Classic Hodgkin Lymphoma

02/24

11/24

ChiCTR1900024904: Exploratory study for IMM01 for injection in refractory or relapsed lymphoma

Recruiting

1/2

Intravenous infusion IMM01

Hematology Hospital, Chinese Academy of Medical Sciences; ImmuneOnco Biopharmaceuticals(Shanghai) Co., Ltd, self-pay

Lymphoma

IMM01-02, NCT05140811: A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Recruiting

1/2

126

RoW

IMM01, IMM01 Ingection, Azacitidine, Vidaza

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Institute of Hematology & Blood Diseases Hospital

Acute Myeloid Leukemia, Myelodysplastic Syndromes

02/24

03/24

NCT05860075: Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Terminated

RoW

IMM01, IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Hematologic Malignancy

10/22

amulirafusp alfa (IMM0306) / ImmuneOnco Biopharma

CTR20192612: Clinical study of IMM0306 in refractory or relapsed CD20-positive B-cell non-Hodgkin lymphoma

Recruiting

1/2

154

China

IMM0306 - ImmuneOnco Biopharma

ImmingOnco Biomedical Technology (Shanghai) Co., Ltd.

Refractory or relapsed CD20-positive B-cell non-Hodgkin lymphoma

NCT06557174: A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Not yet recruiting

1/2

116

IMC-002, mycophenolate mofetil， MMF

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

11/25

07/26

NCT06535412: A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Not yet recruiting

1/2

218

IMC-002 + SOC, Placebo + SOC

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Systemic Lupus Erythematosus

12/25

06/26

IMM0306-003, NCT05771883: A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Not yet recruiting

1/2

102

IMM0306, IMM0306 Ingection, Lenalidomide capsule, Revlimid

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

B-cell Non-Hodgkin's Lymphoma

05/25

11/25

IMM0306-I, NCT05805943: Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Recruiting

1/2

154

RoW

IMM0306

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

CD20-positive B-cell Non-Hodgkin's Lymphoma

05/25

ChiCTR1900028292: A clinical study to evaluate the safety, tolerability and pharmacokinetics of single-and multiple-dose IMM0306 for refractory or relapsed CD20-positive (CD20+) B-cell non-Hodgkin's lymphoma

Recruiting

Intravenous infusion IMM0306

Cancer Hospital Chinese Academy of Medical Sciences; ImmuneOnco Biopharmaceuticals(Shanghai) Co., Ltd, self-pay

refractory or relapsed CD20-positive (CD20+) B-cell non-Hodgkin's lymphoma

vislarafusp-alfa (IMM2902) / ImmuneOnco Biopharma

NCT05805956: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Recruiting

1/2

105

RoW

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma

10/24

ChiCTR2100051718: An open, multi-center, first human dose escalation and early dose expansion phase I clinical study, aimed at evaluating the safety, tolerability and preliminary effectiveness of IMM2902 in the treatment of advanced solid tumors expressing HER2

Recruiting

134

Chinese PLA General Hospital; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Self-funded

Advanced solid tumors expressing HER2

NCT05076591: IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Suspended

135

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer

12/24

palverafusp alpha (AXN-2510) / Instil Bio

NCT06746870: A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

Not yet recruiting

148

IMM2510, Chemotherapy (pemetrexed + cisplatin/carboplatin), Chemotherapy (paclitaxel + cisplatin/carboplatin), Chemotherapy(Nab-paclitaxel)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

NSCLC, TNBC

11/25

12/26

NCT05972460: IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Recruiting

108

RoW

IMM2510, IMM2510 Injection

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Zhejiang Cancer Hospital, Fudan University

Advanced Solid Tumors

12/23

10/24

IMM2510-002, NCT06764836: A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Recruiting

108

RoW

IMM27M, IMM2510

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumors, HCC

01/26

ChiCTR2400085450: An umbrella study of molecular pathway-based precision therapy for neurofibromatosis type 2 (NF2)

Not yet recruiting

N/A

AYK103 + Sindillizumab injection; IMM2510; SW-NF-001

Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, self-funded

NF2

IMM2520 / ImmuneOnco Biopharma

NCT05780307: IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Recruiting

RoW

IMM2520, IMM2520 is a recombinant bispecific monoclonal antibody with high affinity to the dual targets, PD-L1 and CD47

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shandong Cancer Hospital and Institute

Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Squamous Cell Cancer of Head and Neck, Colorectal Cancer

03/24

10/25

IMM40H / ImmuneOnco Biopharma

NCT05549557: IMM40H Phase I Dose Escalation and Expansion

Not yet recruiting

IMM40H, study drug: IMM40H

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Tumor

10/23

06/24

IMM47 / ImmuneOnco Biopharma

NCT05985083: A Study Of IMM47 In Subjects With Advanced Solid Tumors

Recruiting

RoW

IMM47

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., IQVIA RDS

Oncology

12/24

01/25

SYN-27M / Instil Bio

NCT05235438: Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Recruiting

RoW

IMM27M

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Oncology, CTLA4 Haploinsufficiency

08/23

08/24

IMM4701C / ImmuneOnco Biopharma

No trials found

IMM5601 / ImmuneOnco Biopharma

No trials found

IMM6101 / ImmuneOnco Biopharma

No trials found

IMM4701 / ImmuneOnco Biopharma

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

timdarpacept (IMM01) / ImmuneOnco Biopharma

NCT06465446: A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Not yet recruiting

202

Tislelizumab, IMM01, Timdarpacept, Bendamustine, Gemcitabine

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Classic Hodgkin Lymphoma

06/26

07/29

CMML1-2, NCT06647862: IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia

Recruiting

170

RoW

IMM01, Timdarpacept, Azacitidine, Placebo

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Chronic Myelomonocytic Leukemia

04/26

10/29

DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting

RoW

IMC-001, Not confirm yet

ImmuneOncia Therapeutics Inc.

Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma

07/24

02/26

TMB-H, NCT06365840: A Study of IMC-001 In Patients With Metastatic Or Locally Advanced Solid Tumor

Recruiting

RoW

IMC-001

ImmuneOncia Therapeutics Inc.

TMB-H, Histologically or Cytologically Proven Metastatic or Locally Advanced Solid Tumors

12/26

08/29

NCT06788431: A Study of IMC-001 on Improved Atherosclerotic Plaque Stability in Patients of ACS

Recruiting

RoW

IMC-001, Optimal medical treatment

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd., The First Affiliated Hospital of Nanyang Medical College, Renji Hospital, Shanghai

Atherosclerosis

11/25

12/25

IMM01-04, NCT05833984: Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

Recruiting

1b/2

309

RoW

IMM01, SIRPα Fc, Tislelizumab

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Solid Tumor, Classic Hodgkin Lymphoma

02/24

11/24

ChiCTR1900024904: Exploratory study for IMM01 for injection in refractory or relapsed lymphoma

Recruiting

1/2

Intravenous infusion IMM01

Hematology Hospital, Chinese Academy of Medical Sciences; ImmuneOnco Biopharmaceuticals(Shanghai) Co., Ltd, self-pay

Lymphoma

IMM01-02, NCT05140811: A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

Recruiting

1/2

126

RoW

IMM01, IMM01 Ingection, Azacitidine, Vidaza

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Institute of Hematology & Blood Diseases Hospital

Acute Myeloid Leukemia, Myelodysplastic Syndromes

02/24

03/24

NCT05860075: Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic Malignancy

Terminated

RoW

IMM01, IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Hematologic Malignancy

10/22

amulirafusp alfa (IMM0306) / ImmuneOnco Biopharma

CTR20192612: Clinical study of IMM0306 in refractory or relapsed CD20-positive B-cell non-Hodgkin lymphoma

Recruiting

1/2

154

China

IMM0306 - ImmuneOnco Biopharma

ImmingOnco Biomedical Technology (Shanghai) Co., Ltd.

Refractory or relapsed CD20-positive B-cell non-Hodgkin lymphoma

NCT06557174: A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Not yet recruiting

1/2

116

IMC-002, mycophenolate mofetil， MMF

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Neuromyelitis Optica Spectrum Disorder (NMOSD)

11/25

07/26

NCT06535412: A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus

Not yet recruiting

1/2

218

IMC-002 + SOC, Placebo + SOC

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Systemic Lupus Erythematosus

12/25

06/26

IMM0306-003, NCT05771883: A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide

Not yet recruiting

1/2

102

IMM0306, IMM0306 Ingection, Lenalidomide capsule, Revlimid

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

B-cell Non-Hodgkin's Lymphoma

05/25

11/25

IMM0306-I, NCT05805943: Study of IMM0306 in Patients With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin's Lymphoma

Recruiting

1/2

154

RoW

IMM0306

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

CD20-positive B-cell Non-Hodgkin's Lymphoma

05/25

Recruiting

Intravenous infusion IMM0306

Cancer Hospital Chinese Academy of Medical Sciences; ImmuneOnco Biopharmaceuticals(Shanghai) Co., Ltd, self-pay

refractory or relapsed CD20-positive (CD20+) B-cell non-Hodgkin's lymphoma

vislarafusp-alfa (IMM2902) / ImmuneOnco Biopharma

NCT05805956: IMM2902 in Patients With Advanced Solid Tumors Expressing HER2

Recruiting

1/2

105

RoW

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Lung Cancer, Advanced Gastric Carcinoma, Advanced Cholangiocarcinoma

10/24

Recruiting

134

Chinese PLA General Hospital; ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd, Self-funded

Advanced solid tumors expressing HER2

NCT05076591: IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

Suspended

135

IMM2902

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer

12/24

palverafusp alpha (AXN-2510) / Instil Bio

Not yet recruiting

148

IMM2510, Chemotherapy (pemetrexed + cisplatin/carboplatin), Chemotherapy (paclitaxel + cisplatin/carboplatin), Chemotherapy(Nab-paclitaxel)

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

NSCLC, TNBC

11/25

12/26

NCT05972460: IMM2510, a PD-L1 and VEGF Bispecific Fusion Protein, in Patients With Advanced Solid Tumors

Recruiting

108

RoW

IMM2510, IMM2510 Injection

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Zhejiang Cancer Hospital, Fudan University

Advanced Solid Tumors

12/23

10/24

IMM2510-002, NCT06764836: A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors

Recruiting

108

RoW

IMM27M, IMM2510

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Advanced Solid Tumors, HCC

01/26

ChiCTR2400085450: An umbrella study of molecular pathway-based precision therapy for neurofibromatosis type 2 (NF2)

Not yet recruiting

N/A

AYK103 + Sindillizumab injection; IMM2510; SW-NF-001

Shanghai Sixth People's Hospital; Shanghai Sixth People's Hospital, self-funded

NF2

IMM2520 / ImmuneOnco Biopharma

NCT05780307: IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors

Recruiting

RoW

IMM2520, IMM2520 is a recombinant bispecific monoclonal antibody with high affinity to the dual targets, PD-L1 and CD47

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shandong Cancer Hospital and Institute

Advanced Solid Tumor, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Squamous Cell Cancer of Head and Neck, Colorectal Cancer

03/24

10/25

IMM40H / ImmuneOnco Biopharma

NCT05549557: IMM40H Phase I Dose Escalation and Expansion

Not yet recruiting

IMM40H, study drug: IMM40H

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Tumor

10/23

06/24

IMM47 / ImmuneOnco Biopharma

NCT05985083: A Study Of IMM47 In Subjects With Advanced Solid Tumors

Recruiting

RoW

IMM47

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., IQVIA RDS

Oncology

12/24

01/25

SYN-27M / Instil Bio

NCT05235438: Safety and Toxicity Study of IMM27M in Patients With Advanced Solid Tumor

Recruiting

RoW

IMM27M

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Oncology, CTLA4 Haploinsufficiency

08/23

08/24

IMM4701C / ImmuneOnco Biopharma

No trials found

IMM5601 / ImmuneOnco Biopharma

No trials found

IMM6101 / ImmuneOnco Biopharma

No trials found

IMM4701 / ImmuneOnco Biopharma

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites